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FLWe previously generated a rat model that developed systemic connective tissue diseases, including
synovitis, myositis, and small-vessel vasculitis (SVV), and established a vascular endothelial celle
reactive T-cell clone, VASC-1, from the model. VASC-1 was determined to be a type II natural killer T-cell
clone. In this study, we attempted to identify the antigen recognized by VASC-1. The monkey-derived
cell line COS-7 was used because VASC-1 does not bind naturally to COS-7, although the amino acid
sequences are well conserved between monkey CD1d and rat CD1d. We generated 98 COS-7 clones
transfected with miscellaneous rat cDNA and screened them for VASC-1 binding. Consequently, we found
one clone, 4D2, which could bind to VASC-1. Sequencing identiﬁed the rat cDNA introduced into 4D2 as
sterol carrier protein 2 (SCP2). When VASC-1 was co-cultured with SCP2 knockdown rat vascular
endothelial cells, VASC-1 binding was reduced signiﬁcantly. Moreover, we designed a series of rat SCP2
peptides and introduced them into COS-7 cells. On the basis of VASC-1 binding and proliferation, we
revealed that the peptide rSCP2518-532 included the epitope recognized by VASC-1. Furthermore,
immunization with rSCP2518-532 accelerated the development of SVV in the rat model. The collective
ﬁndings suggest that type II natural killer T cells reactive with autologous SCP2 are implicated in
vascular inﬂammation in the rat model. (Am J Pathol 2016, -: 1e11; http://dx.doi.org/10.1016/
j.ajpath.2016.09.014)Supported by grant-in-aid 26293082 from the Ministry of Education,
Culture, Sports, Science and Technology of Japan, a grant for Research on
Rare and Intractable Vasculitis from the Ministry of Health, Labor and
Welfare of Japan, and grant 15ek0109121 from the Japan Agency for
Medical Research and Development Q2. Q3
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123We previously generated a rat model that developed sys-
temic connective tissue diseases, including synovitis,
myositis, and small-vessel vasculitis (SVV).1 In this model,
a predominant inﬁltration of mononuclear cells was
observed in the synovial and cardiac tissues and skeletal
muscles and around small vessels in the systemic organs.
An autoimmune mechanism could be involved in the
pathogenesis because several autoantibodies, such as anti-
nuclear and anti-DNA antibodies, were detected in the
serum. The presence of hyperreactivity of peripheral T
cells,2 disordered differentiation of T cells in the thymus,3
and functional impairment of regulatory T cells4 had been
found in the model. In addition, we recently established a
T-cell clone reactive with autologous vascular endothelial
cells from the rat model and designated the clone asstigative Pathology. Published by Elsevier Inc
Y-NC-ND license (http://creativecommons.org
A 5.4.0 DTD  AJPA2486_proof VASC-1.5 VASC-1 was determined to be a clone of natural
killer T (NKT) cells because this clone recognized a certain
antigen presented by CD1d.
NKT cells belong to a unique subset of T cells that share
surface markers and function with natural killer (NK) cells
and play important roles in the immune response.6 The
hallmark of NKT cells is their capacity to recognize antigens.
/licenses/by-nc-nd/4.0).
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213presented by class I major histocompatibility complexelike
CD1d.7,8 Among the NKT cells, two major subsets, namely,
type I and type II, have been noted.8e10 Type I NKT cells
are characterized by the expression of a conserved T-cell
receptor (TCR) a-chain (Va24-Ja18 in humans and
Va14-Ja18 in rodents) that pairs with a limited repertoire of
b-chains.11e13 This type of cell, also called invariant NKT
cells, can bind to a marine spongeederived glycolipid,
a-galactosylceramide (a-GalCer), presented by CD1d. In
general, it is considered that type I NKT cells can recognize
microorganism-derived glycolipids presented by CD1d and
trigger both the innate and acquired immune responses
against the microorganism. On the contrary, type II NKT
cells express a more variable TCR repertoire and do not
respond to stimulation with a-GalCer. This type of cell
can recognize sulfatides and peptides presented by
CD1d.7,8,14,15 Interestingly, NKT cells reactive with autol-
ogous peptides (suggestive of type II phenotype) exhibit an
immunosuppressive property in healthy mice.16 It can be
considered that the after immunoregulatory mechanisms are
mediated by type II NKT cells in healthy individuals, cells
injured by an immune reaction express autologous peptides
on CD1d and then type II NKT cells that recognize the
autoantigens produce immunosuppressive cytokines to
prevent an excessive spread of inﬂammation.Table 1 Rat SCP2 Peptides
Name*
Amino acid sequence
M T G K M N P Q S A F F Q G K L K I A G N
rSCP2508-522 M T G K M N P Q S A F F Q G K
rSCP2509-523 T G K M N P Q S A F F Q G K L
rSCP2510-524 G K M N P Q S A F F Q G K L K
rSCP2511-525 K M N P Q S A F F Q G K L K I
rSCP2512-526 M N P Q S A F F Q G K L K I A
rSCP2513-527 N P Q S A F F Q G K L K I A G
rSCP2514-528 P Q S A F F Q G K L K I A G N
rSCP2515-529 Q S A F F Q G K L K I A G N
rSCP2516-530 S A F F Q G K L K I A G N
rSCP2517-531 A F F Q G K L K I A G N
rSCP2518-532 F F Q G K L K I A G N
rSCP2519-533 F Q G K L K I A G N
rSCP2520-534 Q G K L K I A G N
rSCP2521-535 G K L K I A G N
rSCP2522-536 K L K I A G N
rSCP2523-537 L K I A G N
rSCP2524-538 K I A G N
rSCP2525-539 I A G N
rSCP2526-540 A G N
rSCP2527-541 G N
rSCP2528-542 N
rSCP2529-543
rSCP2530-544
rSCP2531-545
rSCP2532-546
rSCP2533-547
The boldface peptides represent those with a hydropathy index >0.200.
*The inserted region in 4D2.
2
FLA 5.4.0 DTD  AJPA2486_proof The NKT cell clone, VASC-1, established from the rat
model of systemic connective tissue diseases, exhibited a
TCR use other than the type I invariant TCR a-chain and
did not bind to a-GalCereloaded CD1d; therefore, it was
regarded as a type II NKT cell clone.5 Because VASC-1
produced proinﬂammatory cytokines after an interaction
with autologous vascular endothelial cells, a functional
impairment of the immunoregulatory autoreactive type II
NKT cells could be present in the rat model. In this study,
we attempted to identify the antigen recognized by VASC-1
and discovered an intracellular lipid transfer molecule, sterol
carrier protein 2 (SCP2), as one of the autoantigens.
Materials and Methods
Rats
The rat model of systemic connective tissue diseases estab-
lished in our laboratory1 and maintained under speciﬁc
pathogen-free condition was used. These rats were transgenic
for the env-pX gene of human T-cell leukemia virus type I.
The transgene was expressed ubiquitously in the systemic
organs, including hematopoietic cells. Because the transgene
coded the transcription factor p40tax, which could disturb the
ordinary transcription in the cells but did not code other viralHydropathy
indexM G L A M K L Q S L Q L Q P D K A K L
0.023
0.005
0.092
0.032
0.109
0.099
0.099
M 0.133
M G 0.222
M G L 0.305
M G L A 0.305
M G L A M 0.268
M G L A M K 0.089
M G L A M K L 0.216
M G L A M K L Q 0.127
M G L A M K L Q S 0.215
M G L A M K L Q S L 0.215
M G L A M K L Q S L Q 0.259
M G L A M K L Q S L Q L 0.237
M G L A M K L Q S L Q L Q 0.139
M G L A M K L Q S L Q L Q P 0.115
M G L A M K L Q S L Q L Q P D 0.107
G L A M K L Q S L Q L Q P D K 0.035
L A M K L Q S L Q L Q P D K A 0.026
A M K L Q S L Q L Q P D K A K 0.197
M K L Q S L Q L Q P D K A K L 0.167
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342constructive proteins, these rats were considered as models
with abnormal gene transcription rather than simple models
of human T-cell leukemia virus type I infection. Experiments
were performed in accordance with the Guidelines for the
Care and Use of Laboratory Animals in Hokkaido University
(permission No. 10-0029, 15-0034).
Cells
The rat inferior vena cavaederived vascular endothelial
cells (RECs) and REC-reactive type II NKT cell clone,
VASC-1, were established in our laboratory.5,17 RECs were
maintained in RPMI 1640 medium containing 10% fetal
bovine serum (FBS) and 5  105 mol/L 2-mercaptoethanol
(2-ME). VASC-1 was maintained in RPMI 1640 medium
containing 20% FBS, 5  105 mol/L 2-ME, and 0.01 mg/
mL recombinant rat IL-2 (R&D Systems, Minneapolis,
MN). The monkey kidneyederived ﬁbroblastic cell line,
COS-7, was maintained in Dulbecco’s modiﬁed Eagle’s
medium (DMEM) containing 10% FBS.
Co-Culture of VASC-1 with RECs or COS-7
RECs or COS-7 was grown subconﬂuently in a well of six-
well plates (1  105 per well) at 37C. VASC-1 (2  105
per well) was co-cultured with the cells in RPMI 1640
medium containing 20% FBS, 5  105 mol/L 2-ME, and
0.01 mg/mL recombinant rat IL-2 overnight at 37C. On the
next day, after the removal of the supernatants, theFigure 1 Involvement of CD1d on rat inferior vena cavaederived vascular
(VASC-1) binding. A and B: Representative images of co-cultured VASC-1 with REC
surface protein (D). Experiments were performed in triplicate. Decrease in VASC-1
CD1d using siRNA (E and F). Data are expressed as means  SD (C and F). nZ 3
T-cell receptor.
The American Journal of Pathology - ajp.amjpathol.org
FLA 5.4.0 DTD  AJPA2486_proof remaining cells were washed with the co-culture medium
three times and then observed under a phase-contrast
microscope.
Knockdown of Rat Genes of RECs
RECs were seeded in 6-cm dishes (2  105/dish) and incu-
bated overnight at 37C. On the next day, the culture medium
was replaced with serum-free 2-MEefree RPMI 1640 me-
dium. Thereafter, siRNA for rat CD1d or rat SCP2 or nega-
tive control siRNA (Life Technologies, Tokyo, Japan) was
transfected into RECs using siGENE (Life Technologies) in
accordance with the manufacturer’s instruction. Forty-eight
hours after the siRNA transfection, total RNA was extrac-
ted from RECs using an RNeasy Mini kit (Qiagen, Alameda,
CA). RNA underwent reverse transcription to cDNA using
transcriptase and oligo-dT primers (Promega, Tokyo, Japan).
The primers for rat genes used in this study were CD1d sense:
50-TAGAAGCAGGGAAGCCAGACC-30, CD1d antisense:
50-TCCGCATTTGGCAGGATGTC-30, SCP2 sense: 50-
CTTCACGATTGCTTCTCTACC-30, SCP2 antisense: 50-
CAGTGCTCCACCTTGTCCTTC-30, glyceraldehyde 3-
phosphate dehydrogenase (GAPDH) sense: 50-ATGG-
GAGTTGCTGTTGAAGTCA-30, and GAPDH antisense:
50-CCGAGGGCCCACTAAAGG-30. Real-time PCR was
run as follows: after denaturation at 94C for 2 minutes, 40
cycles of reaction at 94C for 15 seconds and at 62C for 60
seconds were performed using the GoTaq 2-Step RT-qPCR
System (Promega).endothelial cells (RECs) in vascular endothelial cellereactive T-cell clone
s. Knockdown of CD1d of RECs by siRNA at the levels of mRNA (C) and cell
binding to RECs by the inhibition of CD1d using antibody and knockdown of
(F). *P < 0.05, **P < 0.01 (t-test). Scale bars: 10 mm (A); 50 mm (E). TCR,
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459Flow Cytometry
Seventy-two hours after the siRNA transfection, RECs were
detached from the dishes and then allowed to react with the
anti-mouse/rat CD1d antibody WTH-1 (Abcam, Cambridge,
UK) or mouse IgG2a (BD Biosciences, San Jose, CA) was
the isotype control on ice for 20 minutes (1 mg per 106
cells). After washing, the cells were then made to react with
1:2000 diluted phycoerythrin-conjugated donkey anti-
mouse IgG antibody (eBioscience, San Diego, CA) on ice
for 30 minutes. Flow cytometry was conducted using
FACSCanto II (BD Biosciences), and the data were
analyzed using CellQuest Pro software (BD Biosciences).
VASC-1 Binding to RECs or REC Knockdown of CD1d
Twenty-four hours before this experiment, the medium of
VASC-1 was replaced with a fresh one without IL-2. RECs or
REC knockdown of CD1d was reseeded in two-well slide
chambers (1  105 per well) and incubated overnight at
37C. On the next day, carboxyﬂuorescein succinimidyl
esterelabeled VASC-1 (2  105 per well) was co-cultured
with the cells in RPMI 1640 medium containing 20% FBS4
FLA 5.4.0 DTD  AJPA2486_proof and 5 105 mol/L 2-ME for 2 hours at 37C. For reference,
a similar co-culture was conducted in the presence of 1
mg/mL of the anti-CD1d antibody WTH-1. After the removal
of the supernatants, the remaining cells were washed with
PBS once and then ﬁxed by acetone for 5 minutes at room
temperature. The chambers were removed, and then the slide
glasses were mounted with VECTASHIELD (Vector Labo-
ratories, Burlingame, CA), which contains DAPI.
Comparison of Amino Acid Sequences of Monkey CD1d
and Rat CD1d
The alignment analysis of amino acid sequences of monkey
CD1d (XP_007974824) and rat CD1d (NP_058775) was
conducted using Basic Local Alignment Search Tool
(BLAST).
Transfection of Rat Genes into COS-7
COS-7 was grown subconﬂuently in wells of a six-well
plate (1  105 per well) at 37C. Rat cDNA library derived
from the lungs of Sprague-Dawley strain (TKR9543, Takara
Bio, Otsu, Japan) was transfected into COS-7 cells usingFigure 2 Vascular endothelial cellereactive T-cell
clone (VASC-1) binding to COS-7 transfected with
the rat gene. A and B: Representative images of
co-cultured VASC-1 with COS-7. Comparison of amino
acid sequences of monkey CD1d (XP_007974824) and
rat CD1d (NP_058775) (C). Arg78 and Asp79 in the a1
helix (red box) and Asp152 and Thr155 in the a2 helix
(green box), which are critical for antigen presenta-
tion to type I natural killer T cells, are identical (blue
letters). The plus sign indicates that the amino acids
belong to the same amino acid family. Image of
co-cultured VASC-1 with COS-7 that has been trans-
fected with rat gene (D). Experimental procedure that
identiﬁed the COS-7 transfectant with VASC-1 binding,
4D2 (E). IL-5 expression in VASC-1 co-cultured with rat
inferior vena cavaederived vascular endothelial cells
(RECs) or COS-7 transfectants (F). Total RNA was
extracted from VASC-1 that was co-cultured with or
without RECs or COS-7 transfectants overnight. 4D2 is
the COS-7 transfectant that could bind to VASC-1.
Another COS-7 transfectant, 6A4, was used as a con-
trol for 4D2. RT-PCR for IL-5 was performed. Glycer-
aldehyde 3-phosphate dehydrogenase (GAPDH) was
used as an internal reference for RNA extraction. Scale
bar Z 10 mm (A and E). TCR, T-cell receptor.
ajp.amjpathol.org - The American Journal of Pathology
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589FuGENE (Roche Diagnostics, Tokyo, Japan) in accordance
with the manufacturer’s instruction. Because the lungs were
the most susceptible organs of SVV induced by an i.v. in-
jection of VASC-1,5 we used the cDNA library derived
from the lungs. This library contains more than 1  106
pAP3 neoplasmids carrying diverse rat cDNA fragments in
its multiple cloning sites that lie between the T3 and T7
promoters. Seventy-two hours after the transfection, the
cells were exposed to 650 mg/mL of G418 in DMEM and
cultured further for a week at 37C. Live cells were
collected, reseeded sparsely (200 cells per 9-cm dish), and
cultured in DMEM containing 325 mg/mL of G418 at 37C.
One week later, colony-forming live cells were picked under
a phase-contrast microscope and transferred into wells of
24-well plates. Consequently, 98 COS-7 transfectants were
established. These cells were stored at 150C until use.
Veriﬁcation of Rat Gene Insertion in COS-7
Transfectants
DNA was extracted from the aforementioned 98 COS-7
transfectants using a DNeasy Blood and Tissue Mini Kit
(Qiagen). The insertion of rat genes was detected by PCR
using the T3 and T7 promoter primers, which lie at either
end of the multiple cloning sites for rat genes. PCR was run
using AmpliTaq Gold 360 Master Mix (Applied Bio-
systems, Yokohama, Kanagawa) as follows: after denatur-
ation at 94C for 2 minutes, 35 cycles of reaction at 94CThe American Journal of Pathology - ajp.amjpathol.org
FLA 5.4.0 DTD  AJPA2486_proof for 30 seconds, at 55C for 30 seconds, and at 72C for 60
seconds. Electrophoresis of the PCR products through 1%
agarose gel revealed that a single rat gene fragment was
inserted in 45 COS-7 transfectants and more than two
fragments were inserted in 42 COS-7 transfectants, although
no insertion of the rat gene was evident in 11 COS-7
transfectants.
Co-Culture of VASC-1 and COS-7 Transfectants
Twenty-four hours before this experiment, the medium of
VASC-1 was replaced with a fresh one without IL-2. Each
COS-7 transfectant that carried a single rat gene fragment
(n Z 45) was grown subconﬂuently in a well of six-well
plates (1  105 per well) at 37C. VASC-1 (2  105 per
well) was co-cultured with the cells in RPMI 1640 medium
containing 20% FBS and 5  105 mol/L 2-ME overnight
at 37C. On the next day, after the removal of the super-
natants, the remaining cells were washed with the co-culture
medium three times and then observed under a phase-
contrast microscope. A COS-7 transfectant, 4D2, was
found to bind VASC-1.
Detection of Cytokine Expression in VASC-1
Co-Cultured with COS-7 Transfectants
After an overnight co-culture with the COS-7 transfectant,
4D2, according to the same protocol as above, total RNAFigure 3 Involvement of sterol carrier protein
2 (SCP2) of rat inferior vena cavaederived vascular
endothelial cells (RECs) in vascular endothelial
cellereactive T-cell clone (VASC-1) binding. A: Rat
SCP2 cDNA. The yellow box indicates the open
reading ﬂame. The 30-ﬂanking fragment in red
letters had been introduced into 4D2. Effects of
SCP2 knockdown of RECs on SCP2 mRNA expression
(B) and VASC-1 binding (C). Data are expressed as
means  SD (B and C). n Z 3 (C). *P < 0.05,
**P < 0.01 (t-test). TCR, T-cell receptor.
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RNA underwent reverse transcription to cDNA using tran-
scriptase and oligo-dT primers. The primers for rat genes
used in this study were IL-5 sense: 50-GACGAGCAAT-
GAGACGATGAGGCT-30, IL-5 antisense: 50-ACAGTGC-
CCCCTCGGACAGTT-30, and the former GAPDH sense
and GAPDH antisense. PCR was run using AmpliTaq Gold
360 Master Mix as follows: after denaturation at 94C for 30
seconds, 35 cycles of reaction at 58C for 30 seconds and at
72C for 30 seconds. For the positive and negative controls,
VASC-1 was co-cultured with RECs and with another COS-
7 transfectant, 6A4, respectively.
Identiﬁcation of the Rat Gene Transfected into 4D2
DNA was extracted from the COS-7 transfectant, 4D2,
which could bind to VASC-1, using the DNeasy Blood and
Tissue Mini Kit (Qiagen). The transfected rat gene via the
pAP3 neoplasmid was ampliﬁed by PCR using the T3 and
T7 promoter primers, and then the PCR product was
sequenced directly using GenomeLab Dye Terminator
Cycle Sequencing with Quick Start Kit (Beckman Coulter,
Tokyo, Japan). Consequently, the rat gene transfected into
4D2 was identiﬁed to code SCP2.6
FLA 5.4.0 DTD  AJPA2486_proof VASC-1 Binding to RECs or REC Knockdown of SCP2
This assay was performed similarly to the assay for VASC-1
binding to REC knockdown of CD1d.
Transduction of SCP2 Peptides into COS-7
According to the sequence transfected into 4D2, 26 series of
SCP2 peptides were designed. The amino acid sequences
and expected hydropathy indexes18 are listed in Table 1.
The greater the index is, the more hydrophobic the amino
acid becomes. Because CD1d expressed preferably hydro-
phobic peptides, we requested Thermo Fisher Scientiﬁc
(Osaka, Japan) to generate the nine peptides with a hy-
dropathy index >0.200 (Table 1). The BioPORTER Protein
Delivery Reagent (Genlantis, Tokyo, Japan) was applied for
the intracellular delivery of SCP2 peptides according to the
manufacturer’s instruction. In brief, COS-7 was seeded in
two-well slide chambers (1  105 per well) and incubated
overnight at 37C. SCP2 peptides were diluted in PBS
(4 mg/40 mL), and then BioPORTER-coated tubes were
hydrated with the SCP2 peptide solution and diluted to 500
mL with serum-free DMEM. The total volume of Bio-
PORTER/SCP2 peptide complexes was transferred ontoFigure 4 Screening of sterol carrier
protein 2 (SCP2) peptide recognized by
vascular endothelial cellereactive T-cell
clone (VASC-1). A: Screening of nine
SCP2 peptides for the induction of
VASC-1 binding to COS-7. B and C:
Adherent VASC-1 per 100 COS-7 values
were calculated from six random ﬁelds of
view. VASC-1 binding was increased by
the transduction of rSCP2518-532, but not
rSCP2526-540, into COS-7. Data are
expressed as means  SEM (A and C).
n Z 3 (C). *P < 0.05 (t-test). Scale
bar Z 50 mm (B). PBS, phosphate-
buffered saline.
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842COS-7 cells after being washed with serum-free DMEM,
and then these cells were incubated in the culture medium
for 5 hours at 37C.
VASC-1 Binding to COS-7 or COS-7 Transduced SCP2
Peptides
This assay was performed similarly to the assay for VASC-1
binding to RECs.
VASC-1 Proliferation Assay
Twenty-four hours before this experiment, the culture medium
of VASC-1 was replaced with RPMI 1640 medium devoid of
FBS, 2-ME, and rat IL-2. The knockdown for the SCP2 gene
of RECs was conducted as aforementioned. In some wells of
REC knockdown of SCP2, SCP2 peptides (rSCP2518-532 and
rSCP2526-540) were transduced into the cells similarly to the
transduction into COS-7. Thereafter, these cells were washed
with PBS twice. VASC-1 (4  105 per well) was co-cultured
with the cells for 2 hours at 37C. Finally, the supernatants (90
mL) were transferred into wells of a 96-well plate. Ten mi-
croliters of AlamarBlue (Thermo Fisher Scientiﬁc) were added
to each well and incubated for 2 hours at 37C. Thereafter, the
absorbance at 570 nm was measured, and VASC-1 prolifera-
tion was calculated as follows: Proliferation (%) Z (Sample
Well  Blank Well)  100/(Control Well  Blank Well).
Immunization of Rats
SCP2 peptide solution (rSCP2518-532 or rSCP2526-540, 400
mg/mL in dimethyl sulfoxide) was mixed with an equalSCP2 knockdown
in REC by siRNA
Transduction of 
SCP2 peptide
Cell p
0.00
0.50
1.00
                  )
% ( noitarefilorp evitaleR
100
50
0
Control siRNA
*
*
SCP2 knockdown SCP2 knockdown
+
rSCP2518-532
transduction
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FLA 5.4.0 DTD  AJPA2486_proof volume of Freund’s complete adjuvant. The emulsion was
injected into the skin on the back of premorbid young
disease-prone rats (5-week-old male, 100 mL per site  5
sites per rat). Ten days later, the emulsion that contained
SCP2 peptide and Freund’s incomplete adjuvant was pre-
pared and then injected similarly as the ﬁrst immunization.
Four days later, all rats were euthanized for histologic ex-
amination. Six rats were used for rSCP2518-532 immunization,
and seven rats were used for rSCP2526-540 immunization.Histologic Examination
The systemic organs of rats, including the cerebrum, cere-
bellum, thymus, heart, lungs, liver, spleen, pancreas, kidneys,
adrenal glands, testis, skin, muscle, salivary glands, and
lymph nodes, were processed for tissue sections with he-
matoxylin and eosin staining,Masson trichrome staining, and
immunohistochemistry for a-smooth muscle actin (a-SMA).
Immunohistochemistry for a-SMA was performed using the
anti-human a-SMA antibody (1A4) and LSAB2 kit, uni-
versal (Dako, Tokyo, Japan). Brieﬂy, after antigen retrieval
by heat mediation (121C, 15 minutes), consumption of the
endogenous peroxidase activity by exposure to 3% H2O2,
and inhibition of nonspeciﬁc binding by exposure to the
blocking buffer in the kit, the sections were incubated with
1:100 diluted 1A4 for 30 minutes at room temperature. After
removal of unbound antibodies, the sections were next
allowed to react with the biotin-conjugated secondary anti-
body in the kit for 1 hour at room temperature, followed by
development of color according to the kit protocol. The
histologic score of SVV was determined according to the
number of organs with vasculitic lesions (0 for no organ withroliferation
assay
SCP2 knockdown
+
rSCP2526-540
transduction
Figure 5 Identiﬁcation of rSCP2518-532 as the
epitope recognized by vascular endothelial celle
reactive T-cell clone (VASC-1). The proliferation of
VASC-1 that interacted with rat inferior vena
cavaederived vascular endothelial cells (RECs) was
decreased when sterol carrier protein 2 (SCP2) of
RECs had been knocked down. However, the
decrease was canceled by the transduction of
rSCP2518-532, but not rSCP2526-540, into REC
knockdown of SCP2. Data are expressed as
means  SD. n Z 3. *P < 0.05 (t-test).
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Figure 6 Accelerated development of small-vessel vasculitis (SVV) by
immunization with rSCP2518-532. Premorbid young disease-prone rats
(5-week-old males) were immunized with rSCP2518-532 (n Z 6) or
rSCP2526-540 (n Z 7). Two weeks later, histologic examination was con-
ducted. All rats immunized with rSCP2518-532 (nZ 6/6) developed SVV at
7 weeks old. A: Section of cerebrum with hematoxylin and eosin (H&E)
staining. BeD: Sections of skin with HE staining (B), Masson’s trichrome
staining (C), and a-smooth muscle actin immunostaining (D). Arrows in
A and B indicate inﬂammatory cell inﬁltration into the small vessel wall
and perivascular inﬁltration of inﬂammatory cells. Few vasculitic lesions
were observed in rats immunized with the control peptide, rSCP2526-540
(E, no vasculitic change in the small vessel corresponding to A). F:
Comparison of the histologic score according to the number of organs
with vasculitic lesions between rats immunized with rSCP2518-532 and rats
immunized with the control peptide, rSCP2526-540. **P < 0.01 (U-test).
Scale bars Z 200 mm (AeE). Original magniﬁcation: 200 (A and E);
400 (BeD).
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991lesions; 1, 2, and 3 for one, two, and three organs with
lesions; and 4 for four or more organs with lesions).
Statistical Analysis
The t-test was applied for comparison of the mean values
between the two in vitro groups. The Mann-Whitney U-test
was applied for comparison of the two in vivo groups.
P < 0.05 was regarded as statistically signiﬁcant.
Results
Involvement of CD1d on RECs in VASC-1 Binding
When VASC-1 was co-cultured with RECs, VASC-1
became bound to RECs (Figure 1A). The results of our
previous study suggest that RECs present a certain auto-
antigen on CD1d, and VASC-1 recognizes the autoantigen
via TCR (Figure 1B).5 To conﬁrm the involvement of CD1d
on RECs in VASC-1 binding, we attempted to knock down
CD1d of RECs by siRNA. At ﬁrst, we determined whether
siRNA could exactly knock down CD1d of RECs using
real-time RT-PCR and ﬂow cytometry. As a result, both
mRNA and cell surface expression of CD1d were markedly
reduced in RECs transfected with siRNA for CD1d
(Figure 1, C and D). Next, VASC-1 was co-cultured with
RECs in the presence of anti-CD1d antibody or with REC
knockdown of CD1d. As a result, the quantity of VASC-1
bound to RECs was signiﬁcantly reduced by both the in-
hibition and knockdown of CD1d (Figure 1, E and F). These
ﬁndings conﬁrmed the involvement of CD1d on RECs in
VASC-1 binding.
VASC-1 Binding to COS-7 Transfected with the Rat
Gene
Naturally, VASC-1 does not bind to monkey-derived COS-
7 (Figure 2A). It seems likely that the TCR of VASC-1
cannot recognize monkey antigens presented by monkey
CD1d (Figure 2B). However, it is known that CD1d mol-
ecules are well conserved among species. For instance,
Arg78 and Asp79 in the a1 helix and Asp152 and Thr155 in
the a2 helix, which are critical for antigen presentation to
type I NKT cells,19 are identical between monkey CD1d and
rat CD1d (Figure 2C). Therefore, we hypothesized that
VASC-1 could bind to COS-7 if the monkey CD1d would
present rat antigens (Figure 2D). To verify the hypothesis,
rat cDNA library (1  106 diversity) was transfected into
COS-7, and consequently, 98 COS-7 transfectants carrying
various rat genes were established. By screening for VASC-
1 binding under the co-culture condition, a COS-7 trans-
fectant, named 4D2, was found to bind to VASC-1
(Figure 2E). Furthermore, VASC-1 co-cultured with the
COS-7 transfectant 4D2, which could bind to VASC-1, was
able to express IL-5; this was also the case when VASC-1
was co-cultured with RECs (Figure 2F). On the contrary,8
FLA 5.4.0 DTD  AJPA2486_proof no expression of IL-5 was observed in VASC-1 that was
co-cultured with another COS-7 transfectant, 6A4. Because
IL-5 expression was mediated by CD1d-dependent stimu-
lation via TCR,5 the collective ﬁndings suggested that the
TCR of VASC-1 could cross-react with monkey CD1d
when an appropriate rat antigen was presented.
Identiﬁcation of the Rat Gene Transfected into 4D2
DNAsequencing identiﬁed that the rat gene transfected into4D2
was a 30-ﬂanking fragment of the gene coding an intracellular
lipid transfer molecule, SCP2 (Figure 3A). The C-terminal open
reading frame of SCP2 was included in the fragment.
Involvement of SCP2 in VASC-1 Binding to RECs
To determine whether SCP2 could really be involved in
VASC-1 binding to RECs, SCP2 of RECs was knocked down
by siRNA. When we examined the mRNA expression ofajp.amjpathol.org - The American Journal of Pathology
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expression was markedly reduced (Figure 3B). Correspond-
ingly, VASC-1 binding to RECs was decreased signiﬁcantly
by the knockdown of SCP2 (Figure 3C). These ﬁndings sug-
gest the involvement of SCP2 in VASC-1 binding to RECs.½F5
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On the basis of the SCP2 gene sequence that had been
transfected into 4D2, we designed 26 series of SCP2 pep-
tides (Table 1). Because CD1d expressed preferably hy-
drophobic peptides, the nine peptides with a hydropathy
index >0.200 (Table 1) were selected to be generated. To
identify the epitope of SCP2 recognized by VASC-1, the
nine peptides were transduced into COS-7, and then VASC-
1 binding was screened. It is conceivable that cell surface
CD1d molecules have been occupied by putative antigens.
Thus, we used the transfection procedure to express the
SCP2 peptides on CD1d. We also determined that the
addition of SCP2 peptides in the culture medium could not
increase the VASC-1 proliferation co-cultured with REC
knockdown of SCP2 (data not shown). As a result,Figure 7 Schematic diagram of the disease mechanism implicated in vascular
injury of vascular endothelial cells. Under such a situation, the injured vascular
carrier protein 2 (SCP2)] on CD1d to activate type II natural killer T (NKT) cells. Th
by producing anti-inﬂammatory cytokines in a nonvasculitic condition. However, t
rather enhance the vascular inﬂammation by producing proinﬂammatory cytokine
The American Journal of Pathology - ajp.amjpathol.org
FLA 5.4.0 DTD  AJPA2486_proof transduction of rSCP2518-532 induced the highest binding of
VASC-1 to COS-7 (Figure 4A). On the contrary, trans-
duction of rSCP2526-540 did not promote VASC-1 binding to
COS-7 at all. Repeated experiments using rSCP2518-532 and
rSCP2526-540 reproduced similar results (Figure 4, B and C).
Moreover, we found that REC-dependent proliferation of
VASC-1 was decreased signiﬁcantly when SCP2 of RECs
had been knocked down by siRNA and that the decrease
could be canceled by the transduction of rSCP2518-532 but
not rSCP2526-540 (Figure 5). The collective ﬁndings suggest
that rSCP2518-532 includes the epitope recognized by
VASC-1.Accelerated Development of SVV by Immunization with
rSCP2518-532
Next, we determined whether immunization with
rSCP2518-532 could promote the development of SVV. For
this purpose, premorbid young disease-prone rats were used.
Although SVV usually develops in rats >2 months old,1,20
all rats immunized with rSCP2518-532 (n Z 6/6) developed
SVV at 7 weeks old (Figure 6, AeD). The histologic scoresinﬂammation in the rat model. Excessive inﬂammation sometimes results in
endothelial cells present intracellular hydrophobic autoantigens [eg, sterol
ereafter, the activated type II NKT cells function to converge inﬂammation
he impaired type II NKT cells cannot prevent the spread of inﬂammation but
s.
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1186according to the number of organs with vasculitic lesions
were signiﬁcantly higher in rats immunized with
rSCP2518-532 than in those immunized with the control
peptide, rSCP2526-540 (Figure 6, E and F). These results
indicate that rSCP2518-532-reactive cells, including type II
NKT cells, are critically implicated in the development of
vascular inﬂammation in the rat model.½F7
1187
1188
1189
1190
1191
1192
1193
1194
1195
1196
1197
1198
1199
1200
1201
1202
1203
1204
1205
1206
1207
1208
1209
1210
1211
1212
1213
1214
1215
1216
1217
1218
1219
1220
1221
1222
1223
1224
1225
1226
1227
1228
1229
1230
1231
1232
1233
1234
1235
1236
1237
1238
1239Discussion
In the present study, we found that the rat type II NKT cell
clone, VASC-1, can recognize SCP2 peptides presented by
CD1d. CD1d is known as a class I major histocompatibility
complexelike antigen-presenting molecule that prefers to
present hydrophobic antigens, including bacterial glyco-
lipids.6 Although recent studies have revealed that sulfatides
and peptides can be also presented by CD1d,14,15,21 the
hydrophobicity of CD1d is a primary characteristic based on
the molecular structure.
SCP2 is a 13-kDa protein that is implicated in intracel-
lular lipid transfer.22 The N-terminal 32 amino acids of
SCP2 form an amphipathic a-helix domain, which functions
as a lipid carrier and a ligand-binding region simulta-
neously. On the contrary, the hydrophobic surface of the a
helix constitutes a hollow structure with b-strands in the
SCP2 molecule. This hollow structure binds to
phospholipids.
The SCP2 gene fragment that had been transduced in the
COS-7 transfectant with VASC-1 binding, 4D2, lacked the
translation initiation codon for the complete SCP2 molecule.
However, it contained some in-frame codons coding
methionine, which could initiate the subsequent translation
into certain fragmented proteins, including a part of the
b-strands of the SCP2 molecule. It is conceivable that the
SCP2 fragments expressed in 4D2 are hydrophobic in terms
of the expected binding to phospholipids. Therefore, it is
reasonable to consider that the SCP2 peptides can be pre-
sented by CD1d in 4D2. Moreover, this study has revealed
that the SCP2 epitope recognized by VASC-1 is present in
rSCP2518-532. This peptide is the most hydrophobic among
the 26 candidate peptides; hence, it is consistent with the
hydrophobicity of CD1d.
More recently, Girardi et al23 found that peptides, which
included the [FW]-X-X-[ILM]-X-X-W motif, could bind to
mouse CD1d. Although rSCP2518-532 does not include the
CD1d-binding motif, another CD1d-binding peptide,
mCII707-721,
16 does not include the motif either. We
considered that diverse antigens could be presented by
CD1d.
We do not have any evidence to conclude that the SCP2
peptide is the sole autologous antigen presented by CD1d.
Because the CD1d molecule can present diverse kinds of
antigens, such as glycolipids, sulfatides, and peptides,
regardless of the presence of the [FW]-X-X-[ILM]-X-X-W
motif, it seems likely that several peptides derived from10
FLA 5.4.0 DTD  AJPA2486_proof intracellular proteins, if hydrophobic, can be presented by
CD1d. We were probably able to isolate an NKT cell clone
that recognized the SCP2 peptide by chance.
The expression of SCP2 is distributed widely in the lipid
metabolismerelated organs and cells, including the liver
and vascular endothelial cells.24 Although SCP2 is associ-
ated with the pathogenesis of arteriosclerosis,25 the associ-
ation between SCP2 and vasculitides remains unrevealed.
Further studies are needed to clarify the role of SCP2 in the
pathogenesis of vasculitides.
Accumulated studies have revealed the immunoregula-
tory properties of type II NKT cells in the immune reaction.
Liu et al16 found that NKT cells reactive with autologous
peptides (suggestive of type II phenotype) exhibited an
immunosuppressive property in healthy mice. Correspond-
ingly, the activation of type II NKT cells ameliorated the
murine experimental hepatitis.26e28 Furthermore, Terabe
et al29 found that type II NKT cells were essential for the
down-regulation of tumor immunosurveillance in wild-type
mice. On the contrary, the association of the disorder of type
II NKT cells with inﬂammatory diseases is also reported.
Liao et al30 found that the disordered regulation of type II
NKT cells could cause a spontaneous development of colitis
in CD1d transgenic mice. In summary, type II NKT cells
belong to the immunoregulatory T cells, and the disorder of
these cells can be implicated in immune-related inﬂamma-
tory diseases. In our previous study, the type II NKT cell
clone, VASC-1, had proinﬂammatory but not anti-
inﬂammatory properties when made to react with autolo-
gous vascular endothelial cells.5
In conclusion, the collective evidence suggests that a
disordered immunoregulatory function of autoreactive type
II NKT cells can be implicated in the development of
vascular inﬂammation in the rat model. The impairment of
vascular endothelial cell-reactive type II NKT cells with an
immunoregulatory property could be implicated in the
pathogenic modiﬁcation of diverse human vasculitides, in
which vascular endothelial cells are injured by inﬂammation
(Figure 7). Although a full comprehension of the patho-
genesis of vasculitides remains far off, this study can be a
stream of light that illuminates the pathway.References
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